| Literature DB >> 35551639 |
Aymane Bouzidi1,2,3, Hicham Charoute4, Majida Charif5, Ghita Amalou1,2,3, Mostafa Kandil3, Abdelhamid Barakat2, Guy Lenaers6,7.
Abstract
BACKGROUND: Inherited retinal dystrophies (IRD) and optic neuropathies (ION) are the two major causes world-wide of early visual impairment, frequently leading to legal blindness. These two groups of pathologies are highly heterogeneous and require combined clinical and molecular diagnoses to be securely identified. Exact epidemiological studies are lacking in North Africa, and genetic studies of IRD and ION individuals are often limited to case reports or to some families that migrated to the rest of the world. In order to improve the knowledge of their clinical and genetic spectrums in North Africa, we reviewed published data, to illustrate the most prevalent pathologies, genes and mutations encountered in this geographical region, extending from Morocco to Egypt, comprising 200 million inhabitants. MAIN BODY: We compiled data from 413 families with IRD or ION together with their available molecular diagnosis. The proportion of IRD represents 82.8% of index cases, while ION accounted for 17.8%. Non-syndromic IRD were more frequent than syndromic ones, with photoreceptor alterations being the main cause of non-syndromic IRD, represented by retinitis pigmentosa, Leber congenital amaurosis, and cone-rod dystrophies, while ciliopathies constitute the major part of syndromic-IRD, in which the Usher and Bardet Biedl syndromes occupy 41.2% and 31.1%, respectively. We identified 71 ION families, 84.5% with a syndromic presentation, while surprisingly, non-syndromic ION are scarcely reported, with only 11 families with autosomal recessive optic atrophies related to OPA7 and OPA10 variants, or with the mitochondrial related Leber ION. Overall, consanguinity is a major cause of these diseases within North African countries, as 76.1% of IRD and 78.8% of ION investigated families were consanguineous, explaining the high rate of autosomal recessive inheritance pattern compared to the dominant one. In addition, we identified many founder mutations in small endogamous communities. SHORTEntities:
Keywords: Consanguinity; Genetic spectrum; Inherited optic neuropathies; Inherited retinal dystrophies; Molecular diagnosis; North Africa; Phenotypic spectrum
Mesh:
Year: 2022 PMID: 35551639 PMCID: PMC9097391 DOI: 10.1186/s13023-022-02340-7
Source DB: PubMed Journal: Orphanet J Rare Dis ISSN: 1750-1172 Impact factor: 4.303
Fig. 1Classification of inherited retinal dystrophies (IRD) and number of affected families (N)
Fig. 2Distribution of the phenotypes of 194 North African families with non-syndromic IRD. According to disease categories in the center chart, and within each category in the outer charts. ACHM: achromatopsia, ARB: autosomal recessive bestrophinopathy, BVMD: Best vitelliform macular dystrophy, CHM: choroideremia, CRD: cone-rod dystrophy, CNSB: congenital stationary night blindness, EORD: early onset retinal dystrophy, ESCD: enhanced S-cone syndrome, LCA: Leber congenital amaurosis, OCA: oculocutaneous albinism, RP: retinitis pigmentosa, RPA: retinitis punctata albescens, STGD: Stargardt disease
Fig. 3Distribution of the number of families with non-syndromic IRD per causal genes. A Families with retinitis pigmentosa. B Families with cone-rod dystrophy. C Families with Leber congenital amaurosis
Fig. 4Genetic and phenotypic spectrum of North African families with syndromic IRD. A Distribution of the phenotypes of 143 families with syndromic IRD. B distribution of families with Usher syndrome phenotype per causal gene. C Distribution of families with Bardet-Biedl syndrome phenotype per causal gene
Fig. 5Classification of inherited optic neuropathies (ION) and number of affected families (N)
Fig. 6Distribution of the phenotypes of the 71 North African families with ION. According to the disease presentation (syndromic or non-syndromic) in the center chart, and within each category in the outer charts
Frequencies of IRD subtypes across different countries
| Diseases | USA | UK | France | North Africa |
|---|---|---|---|---|
| Occurrence and frequencies | ||||
| RP | 341 (34.1%) | 311 (43.1%) | 922 (47.1%) | 76 (22.2%) |
| STGD | 189 (18.9%) | 45 (6.2%) | 118 (6%) | 8 (2.3%) |
| USH | 81 (8.1%) | 37 (5.1%) | 207 (10.6%) | 61 (17.8%) |
| CD/CRD | 45 (4.5%) | 74 (10.2%) | 140 (7.2%) | 18 (5.3%) |
| Other macular dystrophies | 93 (9.3%) | 37 (5.1%) | 231 (11.8%) | 3 (0.9%) |
| LCA | 14 (1.4%) | 18 (2.5%) | 52 (2.7%) | 41 (12%) |
| BBS | 25 (2.5%) | 7 (1%) | 23 (1.2%) | 46 (13.5%) |
USA data are from Stone et al., 2017 [221], based on the study of 1000 families
UK data are from Carss et al., 2017 [30], based on 722 individuals
French data are from Bocquet et al., 2013 [220], based on 1957 individuals
North Africa IRD data are from this review, based on 342 families
Data are provided as the number of families or individuals with the disease and their relative frequency in-between parenthesis within the cohort
Frequencies of IRD genes across different countries
| Genes | USA | UK | France | North Africa |
|---|---|---|---|---|
| Occurrence and frequencies | ||||
| 173 (22.8%) | 73 (18.1%) | 72 (17.3%) | 16 (4.7%) | |
| 76 (10%) | 61 (15.1%) | 59 (14.1%) | 9 (2.6%) | |
| 48 (6.3%) | 13 (3.2%) | 23 (5.5%) | – | |
| 34 (4.5%) | 7 (1.7%) | 15 (3.6%) | – | |
| 32 (4.2%) | 6 (1.5%) | 20 (4.8%) | 1 (0.3%) | |
| 6 (0.8%) | 16 (4%) | – | 10 (2.9%) | |
| 8 (1.1%) | 8 (2%) | 26 (6.2%) | 34 (9.9%) | |
| 9 (1.2%) | 2 (0.5%) | – | 20 (5.8%) | |
| 4 (0.5%) | 4 (1%) | 1 (0.2%) | 19 (5.6%) | |
| 3 (0.4%) | 4 (1%) | 1 (0.2%) | 10 (2.9%) | |
USA data are from Stone et al., 2017 [221], based on 760 families
UK data are from Carss et al., 2017 [30], based on 404 individuals
French data are from Bocquet et al., 2013 [220], based on 417 individuals
North Africa data are from this review, based on 342 IRD families
Data are provided as the number of families or individuals and with autosomal dominant (AD) or recessive (AR) variants in the gene considered, and their frequency in-between parenthesis within the cohort with a molecular diagnosis